Comparative Pharmacology
Head-to-head clinical analysis: BUSPAR versus MEPRIAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUSPAR versus MEPRIAM.
BUSPAR vs MEPRIAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Partial agonist at serotonin 5-HT1A receptors, leading to reduced serotonergic activity; also has antagonist activity at D2 and 5-HT2 receptors.
Mepriam is a thiazide-like diuretic that inhibits the Na+-Cl- symporter in the distal convoluted tubule, reducing reabsorption of sodium and chloride, leading to increased diuresis and vasodilation.
Initial: 7.5 mg orally twice daily; may increase by 5 mg/day every 2-3 days. Usual: 20-30 mg/day in divided doses; max 60 mg/day.
Adults: 500 mg IV every 24 hours.
None Documented
None Documented
2–3 hours (terminal); clinical context: requires multiple daily dosing; steady-state achieved in ~2 days
The terminal elimination half-life of MEPRIAM is 12–15 hours (mean 13.5 h) in healthy adults, allowing once-daily dosing. In severe renal impairment (CrCl <30 mL/min), half-life may extend to 30–40 hours, requiring dose adjustment.
Renal: 29–63% (primarily as metabolites, <1% unchanged); Fecal: 34–38%; Biliary: minimal
MEPRIAM is predominantly eliminated via renal excretion (approximately 85% as unchanged drug and metabolites) and about 15% via fecal/biliary routes. Renal clearance accounts for ~70% of total clearance.
Category C
Category C
Anxiolytic
Anxiolytic